Welcome to our dedicated page for Quantum-Si Incorporated news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si Incorporated stock.
Quantum-Si Incorporated (NASDAQ: QSI) drives innovation in proteomics through its revolutionary single-molecule detection platform. This dedicated news hub provides investors and researchers with timely updates on the company's advancements in next-generation protein sequencing technology.
Access authoritative updates including product developments, strategic partnerships, and financial disclosures. Our curated collection ensures efficient tracking of QSI's progress in creating integrated hardware-software solutions for biomolecular analysis.
Key coverage areas: platform innovations enhancing protein detection accuracy, research collaborations advancing life sciences, and operational milestones shaping the future of proteomics tools. All content is verified through primary sources to ensure reliability.
Bookmark this page for streamlined access to Quantum-Si's latest developments in transformative protein sequencing solutions. Check regularly for updates that matter to both scientific and investment communities.
Canada Nickel reported positive assay results from drill hole BAN24-20 at its Bannockburn property, located 65 kilometers south of Timmins. The hole intersected 1.11% nickel over 10.1 metres, including 1.32% nickel, 0.17% copper, and 0.55 g/t palladium + platinum over 4.4 metres.
This mineralized interval is situated 138 metres northwest of BAN24-18, which previously intersected 1.61% nickel over 12.0 metres. The company has completed a new BHEM survey in BAN24-20 to test the continuation of high-grade horizons, revealing two separate lenses of mineralization. Follow-up drilling is currently in progress with hole BAN24-21.
Quantum-Si (Nasdaq: QSI) has launched the Platinum Library Prep Kit, V2, an advanced tool for single-molecule protein sequencing. The new kit offers significant improvements in accessibility and efficiency, reducing hands-on preparation time to under two hours while maintaining precision. Key features include:
- 85% success rate in generating libraries and sequencing results
- Requires fivefold less protein input than V1
- Compatible with standard lab equipment
- Optimized for various protein conditions
The innovation aims to make Next-Gen Protein Sequencing™ more accessible to research labs using QSI's benchtop instrument.
Quantum-Si (Nasdaq: QSI) has launched its new protein Barcoding Kit, designed to revolutionize protein research through multiplexed screening. The kit employs peptide barcodes for efficient protein analysis, particularly beneficial for biopharma research applications including lipid nanoparticle optimization and mRNA therapeutics evaluation. Key features include overnight workflow with minimal hands-on time, ability to detect low-abundance proteins, and relative quantitation across a broad dynamic range. The solution aims to reduce time and costs while maintaining high sensitivity for therapeutic development.
Quantum-Si (QSI) announced major technical advances at its Investor & Analyst event, introducing two key platforms: Platinum Pro and Proteus. Platinum Pro, launching in H1 2025, will offer streamlined workflow, reduced processing time, and custom application development. Proteus, launching in H2 2026, represents a new proteomics platform featuring ultrasensitive detection, automated liquid handling, and rapid sequencing chemistry with 90-minute run times.
The company announced strategic partnerships with Avantor for distribution in US/Canada, NVIDIA for enhanced data processing, SkyWater for consumable platform development, and Planet Innovation for manufacturing support.
Quantum-Si (Nasdaq: QSI) has entered into a distribution agreement with Avantor (NYSE: AVTR) for its Next-Generation Protein Sequencing (NGPS) technology portfolio in the U.S. and Canadian markets. The collaboration will enable broader access to QSI's proteomics solutions across various laboratory settings. The platform utilizes single-molecule sequencing technology for protein and biomarker identification, antibody characterization, protein barcoding, and post-translational modification analysis, supporting applications in drug discovery, diagnostics, and clinical research.
Quantum-Si (Nasdaq: QSI) announced a collaboration with NVIDIA to develop its new proteomics platform, Proteus™, and advance its core technologies using NVIDIA AI and accelerated computing. The partnership aims to enhance data processing speeds to handle increased data volume from Proteus. By combining NVIDIA's computing capabilities with Quantum-Si's single-molecule protein sequencing technologies, they plan to develop a robust data processing system for generating protein insights to advance research, drug discovery, and healthcare AI. The company is already utilizing NVIDIA BioNeMo for protein structure prediction tools.
Quantum-Si (QSI) and SkyWater Technology are expanding their collaboration to develop the consumable for Proteus™, QSI's next-generation protein sequencing platform. This builds upon their existing partnership since 2021 on the first-generation Platinum® platform. SkyWater will continue supplying consumables for Platinum Pro while supporting Proteus commercialization. The new platform aims to enable simultaneous large factor protein sequencing with enhanced accuracy. SkyWater, certified to ISO 13485 Quality Standard for Medical Devices, will leverage its Technology as a Service (TaaS) model and manufacturing capabilities to support this development.
Quantum-Si (Nasdaq: QSI) has announced a partnership with Planet Innovation for the development and manufacturing of its novel proteomics platform, Proteus™. Planet Innovation, which currently manufactures QSI's Platinum® Pro instrument, will expand its role to support Proteus instrument development and serve as the contract manufacturing partner. The partnership aims to bring the platform to market in under two years, with Planet Innovation leveraging its team of over 400 experts in scientific instrumentation and medical devices development. The Platinum® Pro instrument is scheduled to debut in the first half of 2025.
Quantum-Si (Nasdaq: QSI) announced that its Board's Compensation Committee has granted 340,460 restricted stock units (RSUs) to a new employee under the 2023 Inducement Plan. The RSUs will vest 25% on December 20, 2025, with the remaining vesting in 12 equal quarterly installments thereafter, subject to continued employment. The grant complies with Nasdaq Listing Rule 5635(c)(4) and serves as an inducement for new employees who were not previously with the company.
Quantum-Si (Nasdaq: QSI) has been awarded Frost & Sullivan's 2024 Technology Innovation Leadership Award in North America for its groundbreaking Platinum® instrument, the first benchtop sequencer offering single-molecule protein sequencing at the amino acid level. The technology enables deep insights into protein structure and function through a compact, accessible, and cost-effective instrument. The Platinum device integrates proprietary image sensors for single-molecule detection and precision sequencing, making protein research more accessible to labs of all sizes. The company's innovation is backed by an extensive intellectual property portfolio of over 1,000 issued and pending patents.
FAQ
What is the current stock price of Quantum-Si Incorporated (QSI)?
What is the market cap of Quantum-Si Incorporated (QSI)?
